V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Eli Lilly and Company Executive Compensation (FY25)

LLY · Executive and director compensation, fiscal 2022 to 2025
Data as of September 7, 2026Latest filing (8-K): May 7, 2026
293 figures on this page: 288 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
Companies named in the disclosed peer group include Abbott Laboratories, Adobe, Advanced Micro Devices, Apple and Applied Materials, among others, and companies named in the RVA peer group include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb and Gilead Sciences, among others. David Ricks was paid $36,698,337 in total compensation as Chair, President, and Chief Executive Officer for fiscal 2025, and for fiscal 2025, the company reported a chief executive pay ratio of 293:1, against median employee compensation of $125,100. For fiscal 2025, shareholders backed the say-on-pay proposal with 96.0% of votes cast for or against in favor at the meeting held May 4, 2026.
Chief executive, fiscal 2025
◇
David Ricks
Latest say-on-pay support
=
May 4, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — David Ricks: $29,242,926 → $36,698,337 (25.5% higher)
Say-on-pay support: 96.3% → 96.0% (0.3 points lower)
CEO pay ratio: 243:1 → 293:1 (20.6% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Eli Lilly and Company's chief executive and what were they paid?
David Ricks was paid $36,698,337 in total compensation as Chair, President, and Chief Executive Officer for fiscal 2025. Compared with the $29,242,926 reported for fiscal 2024, Ricks' total was 25.5% higher.
What was Eli Lilly and Company's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 96.0% of votes cast for or against in favor at the meeting held May 4, 2026.
Which companies are in Eli Lilly and Company's peer group?
Companies named in the disclosed peer group include Abbott Laboratories, Adobe, Advanced Micro Devices, Apple and Applied Materials, among others. Companies named in the RVA peer group include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb and Gilead Sciences, among others.
What is Eli Lilly and Company's chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 293:1, against median employee compensation of $125,100.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David A. Ricks
Chair, President, and Chief Executive Officer
◇—◇—◇—◇◇
Daniel M. Skovronsky
Executive Vice President, Chief Scientific Officer and President, Lilly Research Laboratories and Lilly Immunology
◇—◇—◇—◇◇
Anat Hakim
Executive Vice President, General Counsel and Secretary
◇—◇—◇◇◇◇
Anat Ashkenazi
Executive Vice President and Chief Financial Officer
◇—◇—◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David A. Ricks
Chair, President, and Chief Executive Officer
◇—◇—◇◇◇◇
Daniel M. Skovronsky
Executive Vice President, Chief Scientific Officer and President, Lilly Research Laboratories and Lilly Immunology
◇—◇—◇◇◇◇
Anat Ashkenazi
Executive Vice President and Chief Financial Officer
◇—◇—◇◇◇◇
Anat Hakim
Executive Vice President, General Counsel and Secretary
◇—◇—◇◇◇◇
Jake Van Naarden
EVP & President, Loxo@Lilly
◇◇◇◇◇◇◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David A. Ricks
Chair, President, and Chief Executive Officer
◇—◇—◇◇◇◇
Daniel M. Skovronsky
Executive Vice President, Chief Scientific Officer and President, Lilly Research Laboratories and Lilly Immunology
◇—◇—◇◇◇◇
Anat Hakim
Executive Vice President, General Counsel and Secretary
◇—◇—◇◇◇◇
Jake Van Naarden
Executive Vice President and President, Loxo@Lilly
◇—◇—◇◇◇◇
Anat Ashkenazi
Executive Vice President and Chief Financial Officer
◇—◇——◇◇◇
Lucas Montarce
Executive Vice President and Chief Financial Officer
◇—◇—◇◇◇◇
Gordon Brooks
Interim CFO and Group Vice President - Controller and Corporate Strategy
Served on an interim basis
◇◇◇—◇◇◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David Ricks
Chair, President, and Chief Executive Officer
◇—◇—◇◇◇◇
Daniel Skovronsky
Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Labs
◇—◇—◇◇◇◇
Anat Hakim
Executive Vice President, General Counsel and Secretary
◇—◇—◇◇◇◇
Lucas Montarce
Executive Vice President and Chief Financial Officer
◇—◇—◇◇◇◇
Jake Van Naarden
Executive Vice President and President, Lilly Oncology and Head of Corporate Business Development
◇—◇—◇◇◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Anat HakimPSU_RVA◇—◇◇◇—◇
Anat HakimPSU_SVA◇—◇◇◇—◇
Daniel SkovronskyPSU_SVA◇—◇◇◇—◇
Daniel SkovronskyPSU_RVA◇—◇◇◇—◇
David RicksPSU_RVA◇—◇◇◇—◇
David RicksPSU_SVA◇—◇◇◇—◇
Jake Van NaardenPSU_SVA◇—◇◇◇—◇
Jake Van NaardenPSU_RVA◇—◇◇◇—◇
Lucas MontarcePSU_SVA◇—◇◇◇—◇
Lucas MontarcePSU_RVA◇—◇◇◇—◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Jake Van NaardenRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
David RicksRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Lucas MontarceRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Daniel SkovronskyRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Anat HakimRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Juan Luciano
Lead independent director
◇◇————◇
William Kaelin Jr
◇◇———◇◇
Jamere Jackson
◇◇————◇
Gabrielle Sulzberger
◇◇———◇◇
Ralph Alvarez
◇◇————◇
Katherine Baicker
◇◇————◇
Jonathan Moeller
◇◇————◇
J. Erik Fyrwald
◇◇———◇◇
Mary Lynne Hedley
◇◇————◇
Kimberly Johnson
◇◇————◇
Carolyn Bertozzi
◇—————◇
David A. Ricks served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Deferred Stock Units.
Stock ownership guideline: 5x annual retainer ($550,000)

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Abbott Laboratories ABT
  • Adobe ADBE
  • Advanced Micro Devices AMD
  • Apple AAPL
  • Applied Materials AMAT
  • Broadcom AVGO
  • Cisco CSCO
  • Coca-Cola KO
  • Colgate-Palmolive CL
  • Danaher DHR
  • Honeywell HON
  • IBM IBM
  • Intel INTC
  • McDonald's MCD
  • Micron MU
  • Nike NKE
  • NVIDIA NVDA
  • Qualcomm QCOM
  • Salesforce CRM
  • Tesla TSLA
  • Thermo Fisher Scientific TMO
RVA peer group
  • AbbVie ABBV
  • Amgen AMGN
  • AstraZeneca AZN
  • Bristol-Myers Squibb BMY
  • Gilead Sciences GILD
  • GlaxoSmithKline GSK
  • Johnson & Johnson JNJ
  • Medtronic MDT
  • Merck MRK
  • Novartis NVS
  • Pfizer PFE
  • Roche symbol not shown
  • Sanofi SNY
  • Stryker SYK

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 4, 2026=◇◇◇
2024May 5, 2025=◇◇◇
2023May 6, 2024=◇◇◇
2022May 1, 2023=◇◇◇
2021May 2, 2022=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Eli Lilly and Company files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Eli Lilly and Company disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Eli Lilly and Company sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Eli Lilly and Company's disclosed peer group is defensible, who names Eli Lilly and Company back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
293 figures on this page: 288 cited to the filing that reported them, 5 calculated from figures it prints.
288 cited to the filing
5 calculated from the filing

Documents cited

  1. 0000059478-26-000048
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0000059478-26-000029
    2025 Compensation for Non-Employee Directors · CEO Pay Ratio · Director Compensation · Director Compensation Governance · and 2 more sections
  3. 0000059478-25-000138
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0000059478-25-000107
    Summary Compensation Table
  5. 0000059478-24-000127
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0000059478-24-000099
    Summary Compensation Table
  7. 0000059478-23-000165
  8. 0000059478-23-000120
    Summary Compensation Table
  9. 0000059478-22-000138
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Eli Lilly and Company executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/LLY (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Eli Lilly and Company and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Eli Lilly and Company discloses

The companies named in LLY's own disclosed peer group.

Abbott LaboratoriesAdobeAdvanced Micro DevicesAppleApplied MaterialsBroadcomCiscoCoca-ColaHoneywellIBMIntelMcDonald'sMicronNikeNVIDIAQualcommSalesforceAbbVieAmgenBristol-Myers SquibbGilead SciencesJohnson & JohnsonMedtronicMerck

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy